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Abstract
Background Novel treatments against for tinea
capitis are needed, and the natural aminosterol squal-
amine is a potential topical antidermatophyte drug
candidate.
Objectives This phase II randomized double-blind
placebo-controlled clinical trial aimed at testing the
efficacy and safety of a three-week squalamine
ointment regimen for the treatment of tinea capitis.
Patients Males aged 6–15 years presenting with
tinea capitis were treated with either topical squal-
amine ointment or placebo for 3 weeks. The primary
endpoint was complete clinical cure. The secondary
endpoints were the occurrence of local and/or sys-
temic adverse events, mycological cure, and partial
clinical response. Prospective follow-up of clinical
adverse events was performed daily.
Results Five patients were treated with 1 % squal-
amine ointment and 15 with placebo. No complete
cure was observed. No clinical or biological adverse
event was recorded. A significantly (p = 0.03) better
hair-growth score, indicating a partial clinical
improvement of the tinea capitis lesion, was observed
in the patients treated with squalamine compared to
those treated with placebo.
Conclusion This three-week squalamine ointment
regimen was well tolerated and showed an encourag-
ing partial clinical activity for the treatment of tinea
Trial registration: www.pactr.orgPACTR201306000522355.
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capitis. Further studies are needed to evaluate the
efficacy of topical squalamine alone against tinea
corporis or in combination with a systemic antider-
matophyte drug against tinea capitis.
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Introduction
Tinea capitis is a common fungal infection of the
scalp, hair follicles, and hair shafts [1]. Although it can
affect any age group, it is particularly common in
school-aged children. It is almost exclusively a disease
of childhood, and current evidence suggests that it
occurs more often in children of African or Caribbean
extraction [2]. In the USA, tinea capitis is the most
common dermatophyte infection of childhood, with
90 % of infections caused by the anthropophilic fungi
Trichophyton tonsurans [3, 4]. A recent survey carried
in Mali, a country in Western Africa, found a high
prevalence rate of 55 % of tinea capitis in children
attending at primary school in a suburbs of Bamako
(the capital city of Mali), with a predominance of
anthropophilic dermatophytes [5].
Treatment of tinea capitis is inherently difficult and
protracted. Current treatment options included oral
and topical drugs with oral therapies providing better
outcomes. Griseofulvin remains the only licensed
treatment for children in the UK. Nonetheless, many
dermatology units in the UK use terbinafine as first-
line treatment because it is highly effective, well
tolerated, and adherence to treatment is high [2].
However, in developing countries, the cost of these
treatments remains very high. In this context, devel-
oping an effective and affordable topical therapeutic
seems necessary. In recent years, several reports have
described the antifungal activity of natural products
[6]; among them squalamine was a good drug
candidate [7, 8]. Squalamine is a natural aminosterol,
first isolated from the tissues of the dogfish shark
Squalus acanthias, which possesses numerous thera-
peutic values including antiangiogenic properties [9].
The aim of this study was to evaluate the efficacy of
topical administration of squalamine compared with
placebo in the treatment of tinea capitis in children.
Secondary objectives were to assess the safety and to
estimate the relative efficacy of squalamine against
placebo.
Patients and Methods
Study Design
This was a randomized double-blind placebo-con-
trolled clinical trial conducted in primary school
in Sirakoro–Meguetana, a semi-urban community
located at about 4 km of Bamako. The trial was
registered under the PACTR201306000522355 iden-
tification number in the Pan African Clinical Trial
Registry (www.pactr.org). The trial included an
approximate 2-week screening period and 3-week
treatment period. Patients were randomized to receive
one of two possible treatments: squalamine (petro-
leum jelly with 1 % squalamine ointment) or placebo
(petroleum jelly ointment). Treatment evaluated and
placebo were applied once daily on the lesions for
3 weeks. The investigator, wearing gloves, first
roughly cleaned the scalp and then applied the oint-
ment using his finger. Patients were followed up until
4 weeks after the first dose. Patients were to receive
their medication once a day, preferably in the morning.
A thin layer of ointment (either squalamine or pla-
cebo) was applied topically by the investigator.
Study Patients
The study protocol was approved by the Ethical
Committee of Faculty of Medicine and Dentistry of
the University of Sciences Techniques and Technol-
ogies of Bamako (N 10–82/FMPOS) and was carried
out in accordance with the Good Clinical Practice
standards. Written informed consent was obtained
from each patient and their parents before enrollment.
Eligible patients aged 6–15 years had a clinical
mycological diagnosis of tinea capitis. Patients under-
went complete clinical examination, collection of
material from lesions of tinea capitis for mycological
examination, and blood samples for biochemical and
hematological tests.
Inclusion criteria were male children, aged from 6
to 15 years, attending the primary school of Sirakoro–
Meguetana, with both clinical and mycological
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diagnosis of tinea capitis, normal liver and renal
function tests, and no history of allergy.
Non-inclusion criteria were children with derma-
tophyte infection of the skin and/or who received
systemic antifungal therapy within 3 months before
inclusion or topical antifungal therapy within 1 month
before inclusion. Patients were required to shave their
heads at day 0. Because shaving of head is usual
practice for boys, but not for girls in this population,
girls were not included to avoid stigmatisation.
Randomization and Blinding
The blinding and randomization process was as
follows: JMB added 1 % squalamine to five out of
20 randomly selected tubes containing 20 g of petro-
latum-based ointment. The tubes were anonymized
and identified with a unique number from 1 to 20. Only
JMB knew the randomization key; he was neither
involved in the drug administration nor in the clinical
monitoring of patients. Twenty patients received daily
topical application (either squalamine or placebo)
during 3 weeks. The treatment evaluated and placebo
had the same visual appearance. Neither the clinician
in charge of the patient’s treatment follow-up nor the
patient knew the exact nature of the administered
treatment. The unblinding occurred after the ‘‘freez-
ing’’ of the database before the statistical analysis.
Patient’s Follow-up
At day 0, the patients were clinically examined by
qualified physicians, and dermatophytes lesions were
characterized. Blood samples were collected to eval-
uate kidney and liver functions and blood cell count.
Wood’s light examination was performed in a dark-
ened room to detect ectothrix hair invasion caused by
Microsporum spp. Samples were collected from
dermatophytoses lesions. Tinea capitis lesions were
collected by scraping with a sterile curette and a sterile
compress. In areas of alopecia, scales and broken hair
were collected and used for direct examination. A
second sample collected directly with the sterile
compress was kept at room temperature in sealed
plastic bags and then transported to the Parasitology–
Mycology Laboratory at the University Hospital of
Marseille where samples were inoculated onto Sab-
ouraud cycloheximide agar medium (bioMe´rieux,
France). Cultures were maintained for 6 weeks for
positive culture identification. Positive cultures were
examined macroscopically and microscopically for
species identification on the basis of cultural charac-
teristics, pigment production, and microscopic exam-
ination in chloral-lactophenol cotton blue preparation.
Treatment was started after shaving of the patients’
skull and was administered once daily. Clinical
efficacy and adverse events were also monitored daily.
At day 7, samples were collected from tinea capitis
for mycological examination. Blood sample was
collected for laboratory tests. Finally, administration
of treatment was continued in the absence of cure or
major adverse effects.
At day 21, the samples were collected from lesions
of tinea capitis. Blood samples were also collected to
monitor kidney and liver functions and blood cell
counts. Treatment was ended. The patients with
residual tinea capitis were then treated with 20 mg/
kg/d oral griseofulvin for 6–8 weeks.
Efficacy Evaluations
At each study visit, signs and symptoms of tinea
capitis were assessed and samples of tinea capitis
lesions were collected by the investigator for myco-
logical analysis, as detailed above. The primary
efficacy endpoint was a complete clinical cure at
week 3. The first secondary efficacy endpoint was
mycological cure at week 3. Complete cure was
defined as negative mycology (negative culture) and
clinical cure (no clinical symptoms of tinea capitis,
and normal hair growth). Mycological cure was
defined as negative culture. The second secondary
efficacy endpoint was partial clinical response, which
was quantified using a hair-growth score and the
diameter of lesions. The diameter of lesions was
measured using a sliding caliper gauge. Hair growth
was assessed clinically using a score of 0 (no growth)
to 5 (uniform growth) in comparison with healthy
areas of the patient’s scalp.
Safety Evaluations
Adverse events were assessed by the investigators at
each visit. Safety variables assessed included vital
signs measurements, physical examination, and labo-
ratory test results. There was a particular focus on
aspartate aminotransferase (AST), alanine amino-
transferase (ALT), alkaline phosphatase and total
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bilirubin, and hematological parameters (white blood
cells count, packed cell volume, and platelet counts).
Susceptibility Testing
In vitro susceptibility testing of squalamine against the
patients’ isolates was performed as described in [6]
using the M38-A2 micro-broth dilution protocol of the
Clinical and Laboratory Standards Institute.
Statistical Analysis
Patients were randomized in a 1:3 ratio in the group
treated with squalamine or in the placebo group. To
test the difference between 2 % cure rate in placebo
group and 80 % cure rate in the squalamine group,
with a 5 % type I error and 90 % power, number
needed to treat was 20 patients: five in the squalamine
group and 15 in the placebo group. All data were
collected onto case report forms that were kept
confidential and checked daily by a study supervisor.
Data were entered into a MS ACCESSTM database and
checked by the supervisor. The data were presented as
mean (±standard deviation) for quantitative variables
and percentages for qualitative variables. The primary
endpoint was complete cure. The secondary endpoints
were safety, mycological cure (negative mycology),
and partial clinical response (hair-growth score and/or
reduction in the diameters of lesion). The proportions
of patients with an endpoint in either squalamine or
placebo treatment groups were compared using the
Fisher’s exact test. The same analysis was performed
considering each lesion of tinea capitis, using the
generalized estimating equations option to account for
the non-independence of multiple tinea capitis lesions
in a given patient. Statistical analyses were performed
using SAS, version 9.2 (SAS Institute, Cary, NC). All
tests were two-sided with a p \ 0.05 significance
level.
Results
The study was conducted in May 2011. Twenty male
patients aged 6–15 years were included. Five were
treated with topical squalamine and 15 with placebo.
The data at days 0, 7, and 21 of both squalamine and
placebo groups are tabulated in Table 1. There were
no lost to follow-up. The patients’ baseline
characteristics were homogenous among treatment
groups (Table 1). At day 0, there were 10 and 27
lesions of tinea capitis, mean number of lesions per
child 2 ± 1.2 and 1.8 ± 0.8 (p [ 0.05), in the squal-
amine and placebo groups, respectively.
Microsporum audouinii was the predominant patho-
gen in this study. The MIC of terbinafine was\0.25 mg/l
in all 21 isolates. All patients in the squalamine group
were infected by M. audouinii. The means of MICs of
squalamine were 11.2 ± 4.4 and 12.4 ± 4.2 (p = 0.38)
for M. audouinii isolated in patients in the squalamine
and the placebo groups, respectively.
At day 7 (Table 1), mean diameters of lesions were
4.9 ± 4 and 4 ± 2.7 (p = 0.78) in the squalamine and
placebo groups, respectively. The hair-growth scores
in each group did not differ (p = 1.00). Neither
complete nor mycological cure occurred in any patient
in this study.
At day 21 (Table 1), mean diameters of lesions were
3.9 ± 3.2 versus 4 ± 2.5 (p = 0.92) in the squalamine
and placebo groups, respectively. As shown in Fig. 1,
the mean hair-growth score was significantly higher
(2.1 ± 8.9 vs. 1.1 ± 0.6, p = 0.039) in the squal-
amine group than in the placebo group. A score[1 for
hair growth occurred in 70 % [95 % CI (0.35–0.93)]
versus 18.5 % [95 % CI (0.06–0.38), p = 0.005] in
lesions of tinea capitis in the squalamine and placebo
groups, respectively. Complete cure was not recorded.
However, a negative mycological culture of four tinea
capitis lesions was observed in two (10 %) patients in
the placebo group (p = 1.00). With respect to safety,
no clinical or biological adverse event was prospec-
tively recorded during the entire study.
Discussion
In this study, although no complete tinea capitis cure
occurred in the patients who were treated with topical
squalamine, a statistically significantly higher hair-
growth score within the tinea capitis lesions, indicative
of a partial clinical response, was observed in the
patients treated with squalamine. In fact, the currently
available topical treatment is effective against tinea
capitis only when combined with a systemic antider-
matophyte drug, most probably because the dermato-
phytes are located within the hair [2]. Although
systemic therapy, such as oral griseofulvin, effectively
penetrates the infected hair shaft, topical shampoos,
190 Mycopathologia (2015) 179:187–193
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including ketoconazole and selenium sulfide, are rec-
ommended as adjunctive therapeutic options and to
prevent spread of infection [10–12]. This partial efficacy
of topical squalamine against dermatophytes was in
keeping with recent experimental data on the use of
topical squalamine treatment for Staphylococcus aureus
skin decolonization in mice [13]. In this present study, a
negative dermatophyte culture occurred in two patients
with stable clinical lesions in the placebo group. The
most probable explanation is a false negative culture
results due to relatively low sensitivity of culture for the
diagnosis of dermatophytosis [14], mainly because of
the difficulties in obtaining good quality samples for
dermatophyte culture.
However, this study showed a favorable safety
profile of squalamine when administered topically as
no clinical or biological adverse event was recorded in
the treated patients. Yet, this finding should be
interpreted taking into account the small number of
patients treated. The favorable safety index of topical
squalamine was in line with the recent findings of the
absence of genotoxicity and its low cytotoxic activity
against CHO cells suggesting a low cytogenetic
impact on eukaryotic cells [15]. A phase II study
demonstrated that this aminosterol compound could
be safely administered to cancer patients in a five-day
continuous infusion regimen [16]. Moreover, squal-
amine well tolerated without any major side effects at
doses up to 250 mg/day in adults included in phase III
trials for the treatment of age-related macular degen-
eration and prostate cancer [13]. Although no phar-
macokinetic data are available, it is likely that
squalamine plasma levels when administered topically
Table 1 Clinical and mycological characteristics at baseline and at day 7 and day 21 of follow-up of the children participating to this
double-blind randomized placebo-controlled clinical trial of squalamine ointment for tinea capitis treatment
Day 0 Day 7 Day 21
Squalamine Placebo p Squalamine Placebo p Squalamine Placebo p
N 5 15 – 5 15 – 5 15 –
Clinical evaluation
Number of tinea capitis lesions
Total 10 27 – 10 27 – 10 27 –
Mean per patient (±SD) 2 (±1.2) 1.8 (±0.8) 0.67 2 (±1.2) 1.8 (±0.8) 0.67 2 (±1.2) 1.8 (±0.8) 0.67
Diameter of the lesions
Mean (±SD) 5.1 (±3.9) 4.9 (±2.6) 0.88 4.9 (±4.0) 4.6 (±2.7) 0.78 3.9 (±3.2) 4. (±2.5) 0.92
Hair growth
Mean score (±SD) – – – 1.2 ± 0.4 1.0 (±0.2) 1.00 2.1 (±8.9) 1.1 (±0.6) 0.039
Mycological evaluation
Positive dermatophytes
cultures
100 % 100 % 100 % 100 % 100 % 86.7 % 1.00
Dermatophyte species
Trichophyton soudanense 0 26.5 % 0 % 33 % 0 % 23 % –
Microsporum audouinii 100 % 66.5 % 100 % 60.0 % 100 % 69.3 % –
T. soudanense
and M. audouinii
0 7.0 % 0 7.0 % 0 7.7 % –
Fig. 1 Mean (±SD) hair-growth score in the tinea capitis
lesions treated for 3 weeks with squalamine ointment (n = 10
patients) or placebo (n = 27 patients)
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are much lower than those obtained when adminis-
tered intravenously, thus suggesting that a squalamine
ointment could be safe for topical use. Aminosterols
also possess interesting in vitro antibacterial and
antifungal activities, especially squalamine minimum
inhibitory concentrations (MICs) ranged from 4 to
16 mg/l against various clinical dermatophytes spe-
cies [7, 8]. Thus, using a 1 % squalamine-formulated
petrolatum-based cream ointment, as in the present
study, the local squalamine concentration would
exceed more than 1,000 times the dermatophyte
MIC, suggesting a good microbiological efficiency
for a topical use [13]. With respect to the in vitro
activity of aminosterols against dermatophytes, we
recently showed that another aminosterol derivative
had lower MICs than squalamine [7] and might have
an enhanced activity against dermatophytes.
There were three major limitation of this phase II
clinical trial. First, the children who were randomized
in the squalamine group were infected by the single
M. audouinii species. Thus, this study’s findings can
only cautiously be extrapolated to tinea capitis
caused by other dermatophytes, although in vitro
Trichophyton soudanense was at least as susceptible
to squalamine as M. audouinii. Second, squalamine
ointment was administered once in a day, which
could have been insufficient, regarding the inefficacy
of the available antidermatophyte topical treatments
alone against treat tinea capitis to date [2]. Currently,
the recommended therapy for tinea capitis in children
is a 6- to 8-week course of oral griseofulvin [17]. This
study’s objective to cure 80 % of the children in
3 weeks can retrospectively be regarded as too
optimistic and even unrealistic. Nonetheless, consid-
ering the randomized double-blind design, the partial
clinical response evidenced in this study should be
considered as a very encouraging result. In 2007, a
Cochrane review of systemic antifungal treatment for
tinea capitis in children concluded that newer treat-
ments, including terbinafine, have equivalent effi-
cacy and safety profiles to griseofulvin and allow
shorter treatment [2]. Lipozencic et al. [18], in a
double-blind randomized trial in children with tinea
capitis due to Microsporum spp, concluded that
terbinafine therapy for 6 weeks could represent an
alternative to griseofulvin for the treatment of
Microsporum tinea capitis. The third limitation was
that the dose of squalamine applied daily on the
lesions was not quantified. A number of antifungal
drugs with proven efficacy are available for the
treatment of tinea capitis. However, varying dosage
schedules, changes in epidemiology, and increasing
drug resistance are factors that might hamper treat-
ment’s efficacy [19]. The partial clinical response
found in this phase II study suggests that topical
squalamine would be active against tinea corporis,
which is usually treated with topical antifungals
alone or against tinea capitis in combination with a
systemic antifungal. In our setting, systemic antider-
matophyte agent such griseofulvin should be pre-
ferred because of its relatively lower cost and the high
prevalence of Microsporum sp. in this population.
Conclusion
This phase II study evidenced the safety of topical
squalamine treatment and a partial clinical efficacy of
a three-week regimen for the treatment of tinea capitis
lesions. This encouraging result supports further
studies, which should aim at evaluating the efficacy
of various doses of squalamine ointments as mono-
therapy against tinea corporis or in combination with a
systemic antifungal like griseofulvin against tinea
capitis. In both situations, squalamine has the potential
to shorten dermatophytosis treatment duration with
subsequent improvement of compliance to treatment
schedules and costs reduction.
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